All Outputs (155)

ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer (2024)
Journal Article
Patel, R., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., …Green, A. R. (in press). ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer. Pathobiology, https://doi.org/10.1159/000539564

Purpose: ATF4, a stress-responsive transcription factor that upregulates adaptive genes, is a potential prognostic marker and modulator of glutamine metabolism in breast cancer. However, its exact role remains to be elucidated. Methods: ATF4 expre... Read More about ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer.

Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study (2024)
Journal Article
Azam, A. S., Tsang, Y., Thirlwall, J., Kimani, P. K., Sah, S., Gopalakrishnan, K., …Snead, D. R. J. (2024). Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study. Histopathology, 84(5), 847-862. https://doi.org/10.1111/his.15129

Aims: To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods: A total of 2024 cases (608 breast, 607 GI, 6... Read More about Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study.

The amino acid transporter SLC7A11 expression in breast cancer (2023)
Journal Article
Nath, P., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., …Green, A. R. (2024). The amino acid transporter SLC7A11 expression in breast cancer. Cancer Biology and Therapy, 25(1), Article 2291855. https://doi.org/10.1080/15384047.2023.2291855

Breast cancer (BC), characterized by its diverse molecular profiles and clinical outcomes, presents a significant challenge in the development of effective therapeutic strategies. Metabolic reprogramming, a defining characteristic of cancer, has emer... Read More about The amino acid transporter SLC7A11 expression in breast cancer.

Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways (2023)
Journal Article
Saidy, B., Vasan, R., Durant, R., Greener, M., Immanuel, A., Green, A. R., …Storr, S. J. (2023). Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways. Scientific Reports, 13(1), Article 21163. https://doi.org/10.1038/s41598-023-48198-y

DARPP-32 is a key regulator of protein-phosphatase-1 (PP-1) and protein kinase A (PKA), with its function dependent upon its phosphorylation state. We previously identified DKK1 and GRB7 as genes with linked expression using Artificial Neural Network... Read More about Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways.

A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease (2023)
Journal Article
Storr, S. J., Hoskin, V., Aiyappa‐Maudsley, R., Ghaffari, A., Varma, S., Green, A., …Martin, S. G. (2023). A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease. Cancer Medicine, 12(9), 10908-10916. https://doi.org/10.1002/cam4.5802

Introduction: The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to da... Read More about A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease.

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer (2022)
Journal Article
Saunus, J. M., De Luca, X. M., Northwood, K., Raghavendra, A., Hasson, A., McCart Reed, A. E., …Lakhani, S. R. (2022). Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. npj Breast Cancer, 8(1), Article 57. https://doi.org/10.1038/s41523-022-00425-x

Intratumoral heterogeneity is caused by genomic instability and phenotypic plasticity, but how these features co-evolve remains unclear. SOX10 is a neural crest stem cell (NCSC) specifier and candidate mediator of phenotypic plasticity in cancer. We... Read More about Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.

Breast tumor microenvironment structures are associated with genomic features and clinical outcome (2022)
Journal Article
Danenberg, E., Bardwell, H., Zanotelli, V. R. T., Provenzano, E., Chin, S. F., Rueda, O. M., …Ali, H. R. (2022). Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nature Genetics, 54, 660–669. https://doi.org/10.1038/s41588-022-01041-y

The functions of the tumor microenvironment (TME) are orchestrated by precise spatial organization of specialized cells, yet little is known about the multicellular structures that form within the TME. Here we systematically mapped TME structures in... Read More about Breast tumor microenvironment structures are associated with genomic features and clinical outcome.

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer (2021)
Journal Article
Alfarsi, L. H., Ansari, R. E., Craze, M. L., Mohammed, O. J., Masisi, B. K., Ellis, I. O., …Green, A. R. (2021). SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 189(2), 317-331. https://doi.org/10.1007/s10549-021-06298-1

Purpose: Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The... Read More about SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.

Adenomyoepithelioma of the breast: A proposal for classification (2021)
Journal Article
Rakha, E., Hoon Tan, P., Ellis, I., & Quinn, C. (2021). Adenomyoepithelioma of the breast: A proposal for classification. Histopathology, 79(4), 465-479. https://doi.org/10.1111/his.14380

Breast lesions with a prominent myoepithelial cell component constitute a heterogeneous group of benign and malignant neoplastic proliferations. These lesions are often dual epithelial‐myoepithelial but may be purely myoepithelial cell in nature. Ben... Read More about Adenomyoepithelioma of the breast: A proposal for classification.

PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression (2021)
Journal Article
Saidy, B., Kotecha, S., Butler, A., Rakha, E., Ellis, I., Green, A., …Storr, S. (2021). PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression. Journal of Cellular and Molecular Medicine, 25(11), 5015-5024. https://doi.org/10.1111/jcmm.16447

Cyclic-AMP dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) are proteins involved in numerous essential signalling pathways that modulate physiological and pathological functions. Both PP1 and PKA can be inhibited by dopamine and cAMP... Read More about PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression.

Age-related biology of early-stage operable breast cancer and its impact on clinical outcome (2021)
Journal Article
Cheung, K. L., Ellis, I. O., Morgan, D. A., Rakha, E. A., Green, A. R., & Syed, B. M. (2021). Age-related biology of early-stage operable breast cancer and its impact on clinical outcome. Cancers, 13(6), Article 1417. https://doi.org/10.3390/cancers13061417

As age advances, breast cancer (BC) tends to change its biological characteristics. This study aimed to explore the natural progression of such changes. The study included 2383 women with clinically T0-2N0-1M0 BC, managed by primary surgery and optim... Read More about Age-related biology of early-stage operable breast cancer and its impact on clinical outcome.

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray (2020)
Journal Article
Parks, R. M., Albanghali, M. A., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2021). Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray. Breast Cancer Research and Treatment, 185(3), 647-655. https://doi.org/10.1007/s10549-020-06023-4

© 2020, The Author(s). Purpose: Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor (HER)-2. This study uses a uniq... Read More about Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance (2020)
Journal Article
Campbell, C., Mathew, J., Ellis, I. O., Bradbury, I., Borgquist, S., Elebro, K., …Robertson, J. F. R. (2020). Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance. Translational Breast Cancer Research, 1, Article 29. https://doi.org/10.21037/tbcr-20-31

Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample type... Read More about Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance.

Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the uk age rct (2020)
Journal Article
Duffy, S., Vulkan, D., Cuckle, H., Parmar, D., Sheikh, S., Smith, R., …Moss, S. (2020). Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the uk age rct. Health Technology Assessment, 24(55), 1-24. https://doi.org/10.3310/hta24550

Background There remains disagreement on the long-term effect of mammographic screening in women aged 40-49 years. Objectives The long-term follow-up of a randomised controlled trial that offered annual mammography to women aged 40-49 years. The esti... Read More about Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the uk age rct.

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial (2020)
Journal Article
Duffy, S. W., Vulkan, D., Cuckle, H., Parmar, D., Sheikh, S., Smith, R. A., …Moss, S. M. (2020). Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncology, 21(9), 1165-1172. https://doi.org/10.1016/S1470-2045%2820%2930398-3

Background: The appropriate age range for breast cancer screening remains a matter of debate. We aimed to estimate the effect of mammographic screening at ages 40–48 years on breast cancer mortality. Methods: We did a randomised, controlled trial... Read More about Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets (2020)
Journal Article
Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E., Fujii, T., …Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 22, Article 85. https://doi.org/10.1186/s13058-020-01324-4

© 2020 The Author(s). Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable... Read More about Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome (2020)
Journal Article
Parks, R. M., Albanghali, M., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2020). Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome. Cancers, 12(8), Article 2067. https://doi.org/10.3390/cancers12082067

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The majority of biological profiling studies use surgical excision (SE) samples, excluding patients receiving nonsurgical and neoadjuvant therapy. We propose using core needle biopsy (CNB) for... Read More about Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome.

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer (2020)
Journal Article
Abdel-Fatah, T. M., Ball, G. R., Thangavelu, P. U., Reid, L. E., Reed, A. E. M., Saunus, J. M., …Chan, S. Y. (2020). Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer. JAMA Network Open, 3(7), Article e209486. https://doi.org/10.1001/jamanetworkopen.2020.9486

Importance There is no proven test that can guide the optimal treatment, either endocrine therapy or chemotherapy, for estrogen receptor–positive breast cancer. Objective To investigate the associations of sperm-associated antigen 5 (SPAG5) tran... Read More about Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer (2020)
Journal Article
Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), Article 425. https://doi.org/10.1186/s12885-020-06939-6

Background PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important pro... Read More about PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer (2020)
Journal Article
Ansari, R., Craze, M. L., Alfarsi, L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 181(1), 1-12. https://doi.org/10.1007/s10549-020-05586-6

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequenc... Read More about The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.